Key result
Cryoablation of para-Hisian and mid-septal accessory pathways achieved an 81% long-term success rate at 150 months, significantly reducing symptoms (12% vs 96%) and antiarrhythmic drug use.
Why the study?
Cryoablation of septal accessory pathways in Wolff-Parkinson-White Syndrome lacks long-term follow-up data.
Does a specific stepwise cryoablation protocol improve long-term outcomes in patients with para-Hisian and mid-septal accessory pathways?
Cohort (n=26)
Does a specific stepwise cryoablation protocol improve long-term outcomes in patients with para-Hisian and mid-septal accessory pathways?
A specific stepwise cryoablation protocol for para-Hisian and mid-septal accessory pathways demonstrates remarkable long-term safety and efficacy, with significant symptom reduction even in patients with acute procedural failure.
May reduce long-term symptoms in para-Hisian pathways; leaves open need for randomized confirmation.
BACKGROUND: Although cryoablation (CA) of septally located accessory pathways (APs) is an established treatment for Wolff-Parkinson-White Syndrome, its major limitation is the lack of data regarding long-term follow-up (FU). The present study sought to investigate long-term outcomes of a specific CA protocol targeting para-Hisian (P-H) and mid-septal (M-S) APs. METHODS: Twenty-six patients who previously underwent CA of PH or MS APs from 2004 to 2014, were prospectively considered to receive a FU during 2021. All subjects received an outpatient control visit, performing an exercise stress test and a 24-h ECG Holter monitoring. RESULTS: Acute success was achieved in 22 patients (85%). One case of recurrence was reported at short-term FU. Long-term FU, performed after a mean time of 150±37 months, did not show ventricular preexcitation recurrences, with a success rate of 81%, and without late adverse events. Symptoms reduction (12% vs. 96%, P<.001) and lower rates of antiarrhythmic drug use (12% vs. 62%, P<.001) were observed at long term-FU with respect to baseline. This clinical outcome was detected also among patients who underwent unsuccessful CA at baseline. CONCLUSIONS: Our CA protocol confirmed remarkable safety and efficacy throughout a long-term FU. Significant clinical improvement in terms of antiarrhythmic therapy discontinuation and symptoms reduction was also shown among patients who experienced acute failure of CA.
No takes yet. Share an insight, caveat, or question.
Mitacchione et al. (2022) conducted a cohort in Wolff-Parkinson-White Syndrome with para-Hisian and mid-septal accessory pathways (n=26). Stepwise cryoablation protocol vs. Baseline was evaluated on Long-term success (absence of ventricular preexcitation recurrences). Cryoablation of para-Hisian and mid-septal accessory pathways achieved an 81% long-term success rate at 150 months, significantly reducing symptoms (12% vs 96%) and antiarrhythmic drug use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Minerva Cardiology and Angiology